دورية أكاديمية
Landiolol: An Ultra-Short-Acting β-Blocker.
| العنوان: | Landiolol: An Ultra-Short-Acting β-Blocker. |
|---|---|
| المؤلفون: | Rao SJ; From the Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD., Kanwal A; Department of Cardiology, Westchester Medical Center, Valhalla, NY., Kanwal A; George Washington University School of Medicine, Washington, DC., Danilov A; New York Medical College, Valhalla, NY., Frishman WH; Department of Cardiology, Westchester Medical Center, Valhalla, NY.; Department of Medicine, New York Medical College, Valhalla, NY. |
| المصدر: | Cardiology in review [Cardiol Rev] 2024 Sep-Oct 01; Vol. 32 (5), pp. 468-472. Date of Electronic Publication: 2023 Apr 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9304686 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-4683 (Electronic) Linking ISSN: 10615377 NLM ISO Abbreviation: Cardiol Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1998- : Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Baltimore, Md. : Williams & Wilkins, c1993- |
| مواضيع طبية MeSH: | Urea*/analogs & derivatives , Urea*/therapeutic use , Urea*/pharmacology , Morpholines*/therapeutic use , Morpholines*/pharmacology , Adrenergic beta-Antagonists*/therapeutic use, Humans ; Atrial Fibrillation/drug therapy ; Tachycardia/drug therapy |
| مستخلص: | Landiolol is an ultra-short-acting, highly cardio-selective, β-blocker, that is currently approved for clinical use in Japan and the European Union, for the treatment of tachyarrhythmias. Landiolol is highly cardio-selective with high β1 selectivity and receptor affinity, resulting in a more potent chronotropic effect and less potent hypotensive effect compared with other β-blockers such as esmolol and propranolol. Based on the recent randomized controlled trials, low-dose landiolol may have a beneficial role in the prevention and management of postoperative atrial fibrillation following noncardiac and cardiac surgeries, including on-pump and off-pump coronary artery bypass grafting and valve surgery. Additionally, landiolol may have potential utility for myocardial salvage and prevention of postpercutaneous coronary intervention myocardial infarction. Furthermore, the use of landiolol may also have a therapeutic effect for rate control of sepsis-related tachyarrhythmias. Positive results of recent randomized controlled trials should continue to inspire clinicians to conduct further, larger studies, to find new potential clinical applications for this novel drug. Competing Interests: The authors have no conflicts of interest to report. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013;73:959–977. A Short-Acting Selective β1 Blocker, ONOACT for Intravenous Infusion 50mg/150mg Approved for Additional Indication of Ventricular Arrythmia in Japan (revised March 2019). 2019. Available at: https://www.ono-pharma.com/sites/default/files/en/news/press/sm_cn190326.pdf . Accessed November 14, 2022. Rapibloc 300 mg and 600 mg powder for solution for infusion: summary of product characteristics. 2017. Available at: https://mri.cts-mrp.eu . Accessed November 14, 2022. Rapibloc 20 mg/2 ml concentrate for solution for injection: summary of product characteristics. 2017. Available at: http://www.medicinesauthority.gov.mt . Accessed November 14, 2022. Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull (Tokyo). 1992;40:1462–1469. Tsuchiya H, Mizogami M. Characteristic interactivity of landiolol, an ultra-short-acting highly selective β1-blocker, with biomimetic membranes: comparisons with β1-selective esmolol and non-selective propranolol and alprenolol. Front Pharmacol. 2013;4:150. Syed YY. Landiolol: a review in tachyarrhythmias. Drugs. 2018;78:377–388. Sasao J, Tarver SD, Kindscher JD, et al. In rabbits, landiolol, a new ultra-short-acting beta-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmolol. Can J Anaesth J Can Anesth. 2001;48:985–989. Ikeshita K, Nishikawa K, Toriyama S, et al. Landiolol has a less potent negative inotropic effect than esmolol in isolated rabbit hearts. J Anesth. 2008;22:361–366. Shibata S, Okamoto Y, Endo S, et al. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118:255–265. Nasrollahi-Shirazi S, Sucic S, Yang Q, et al. Comparison of the β-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. J Pharmacol Exp Ther. 2016;359:73–81. Krumpl G, Ulc I, Trebs M, et al. Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. Eur J Clin Pharmacol. 2017;73:417–428. Krumpl G, Ulč I, Trebs M, et al. Pharmacodynamic and -kinetic behavior of low-, intermediate-, and high-dose landiolol during long-term infusion in whites. J Cardiovasc Pharmacol. 2017;70:42–51. Krumpl G, Ulč I, Trebs M, et al. Pharmacokinetics and pharmacodynamics of low-, intermediate-, and high-dose landiolol and esmolol during long-term infusion in healthy whites. J Cardiovasc Pharmacol. 2018;71:137–146. Tsunekawa K, Imawaka H, Yamamoto K, et al. Studies on the metabolic fate of ultra short acting.BETA.1 blocker ONO-1101. (3). Metabolism and protein binding. Drug Metab Pharmacokinet. 1997;12:31–41. Krumpl G, Ulc I, Trebs M, et al. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2016;92:64–73. Ojima T, Iwahashi M, Nakamori M, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2014;44:839–847. Murthy SC, Law S, Whooley BP, et al. Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality. J Thorac Cardiovasc Surg. 2003;126:1162–1167. Yoshida T, Furukita Y, Yamamoto Y, et al. A randomized, open label study of the efficacy of prophylactic 24-h low-dose landiolol for atrial fibrillation in transthoracic esophagectomy. Esophagus. 2017;14:97–103. Ojima T, Nakamori M, Nakamura M, et al. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg. 2017;104:1003–1009. Horikoshi Y, Goyagi T, Kudo R, et al. The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: a randomized controlled clinical trial. J Clin Anesth. 2017;38:111–116. Sezai A, Minami K, Nakai T, et al. Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial. J Thorac Cardiovasc Surg. 2011;141:1478–1487. Sezai A, Nakai T, Hata M, et al. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study. J Thorac Cardiovasc Surg. 2012;144:1241–1248. Fujii M, Bessho R, Ochi M, et al. Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery. J Cardiovasc Surg (Torino). 2012;53:369–374. Ogawa S, Okawa Y, Goto Y, et al. Perioperative use of a beta blocker in coronary artery bypass grafting. Asian Cardiovasc Thorac Ann. 2013;21:265–269. Nagaoka E, Arai H, Tamura K, et al. Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting. Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia. 2014;20:129–134. Sakaguchi M, Sasaki Y, Hirai H, et al. Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery. Int Heart J. 2012;53:359–363. Sakamoto A, Kitakaze M, Takamoto S, et al. Landiolol, an ultra-short-acting β 1 -blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ J Off J Jpn Circ Soc. 2012;76:1097–1101. Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting.BETA.1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76:439–445. Park H, Otani H, Noda T, et al. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention. Int J Cardiol. 2013;167:1547–1551. Miyamoto M, Osawa K, Miyoshi T, et al. Efficacy and safety of early intravenous landiolol on myocardial salvage in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention: a randomized study. Acta Med Okayama. 2021;75:289–297. Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36:1701–1706. Calvin JE, Driedger AA, Sibbald WJ. An assessment of myocardial function in human sepsis utilizing ECG gated cardiac scintigraphy. Chest. 1981;80:579–586. Rumery K, Yunus F, Frishman WH. Myocardial depression in sepsis: beneficial adaptation or sequelae that requires treatment? Cardiol Rev. 2020;28:256–261. Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015;4:251. Yoshida Y, Hongo T, Sakamoto A, et al. Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol. Anesth Analg. 2005;100:294. Kakihana Y, Nishida O, Taniguchi T, et al.; J-Land 3S Study Group. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;8:863–872. Unger M, Morelli A, Singer M, et al. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials. 2018;19:637. |
| المشرفين على المادة: | 62NWQ924LH (landiolol) 8W8T17847W (Urea) 0 (Morpholines) 0 (Adrenergic beta-Antagonists) |
| تواريخ الأحداث: | Date Created: 20230515 Date Completed: 20240805 Latest Revision: 20240805 |
| رمز التحديث: | 20240806 |
| DOI: | 10.1097/CRD.0000000000000555 |
| PMID: | 37185629 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1538-4683 |
|---|---|
| DOI: | 10.1097/CRD.0000000000000555 |